AbbVie is a global biopharmaceutical company that focuses on the research, development, and commercialization of advanced therapies to treat complex diseases across multiple therapeutic areas, including immunology, oncology, neuroscience, and virology. The company is known for its innovative biologics and pharmaceutical products aimed at addressing unmet medical needs, improving patient outcomes, and enhancing the quality of life for individuals suffering from chronic and acute health conditions. Through a combination of scientific expertise and strategic partnerships, AbbVie continuously strives to push the boundaries of medical science and expand its portfolio of leading-edge treatments. Read More
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But speed bumps such as inventory destockings have persisted in the wake of COVID-19, limiting growth.
This has capped returns as the industry’s six-month gain of 6.5% has lagged the S&P 500’s 24.7% climb.
On October 2, 2025, the Healthcare sector emerged as a beacon of stability and growth within the S&P 500, delivering a robust positive performance that significantly contributed to the broader market's resilience. Despite prevailing anxieties, including a looming U.S. government shutdown and a disappointing jobs report, healthcare equities
Stay tuned for the market movements in the S&P500 index on Thursday. Check out the gap up and gap down stocks in the S&P500 index during today's session.
New York, NY – October 1, 2025 – In a surprising turn of events on Wall Street today, the healthcare sector emerged as the undisputed leader, shrugging off the dual anxieties of a U.S. government shutdown and a disappointing jobs report. As investors sought refuge in defensive plays and reacted to
Shares of pharmaceutical company AbbVie (NYSE:ABBV) jumped 5.2% in the afternoon session after the company submitted a biologics license application (BLA) to the U.S. Food and Drug Administration (FDA) for its drug candidate pivekimab sunirine. The company is developing the molecule as a potential treatment for blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare and highly aggressive blood cancer, as well as acute myeloid leukemia (AML). Investor optimism was further bolstered by AbbVie's announcement of a $70 million expansion of its Bioresearch Center in Massachusetts to increase its U.S. biologics manufacturing and R&D capabilities. This move is part of a larger investment to strengthen domestic operations, potentially shielding the company from pharmaceutical tariffs. The positive news, which followed the stock reaching an all-time high on the previous day, appeared to outweigh a downgrade from HSBC to 'Hold' from 'Buy'.
The global healthcare sector is currently navigating a period of profound transformation, driven by aggressive regulatory changes emanating from the United States. As of late September 2025, a series of White House initiatives and legislative actions, most notably the ongoing implementation of the Inflation Reduction Act (IRA) and the pursuit
September 30, 2025 – The healthcare sector today finds itself at a pivotal juncture, experiencing a complex mix of optimism and apprehension. While a landmark drug-pricing agreement between pharmaceutical giant Pfizer (NYSE: PFE) and the U.S. government has sparked a "relief rally" for some major players, the broader market remains
New York, NY – September 30, 2025 – AMN Healthcare Services (NYSE: AMN), a leading provider of healthcare staffing solutions, witnessed a significant upward movement in its stock today, reflecting a broader market optimism rippling through the healthcare sector. While AMN's direct stock drivers often stem from company-specific operational successes, today's surge
Washington D.C. – September 30, 2025 – The pharmaceutical sector experienced a significant upward surge today, notably led by AbbVie (NYSE: ABBV), following reports of a groundbreaking drug-pricing agreement reached between the White House and a major pharmaceutical player, Pfizer (NYSE: PFE). This development has been widely interpreted by investors as
A number of stocks jumped in the afternoon session after reports revealed a potential drug-pricing agreement between the White House and the pharmaceutical industry.
AbbVie (NYSE: ABBV) has outperformed the market over the past 5 years by 6.25% on an annualized basis producing an average annual return of 20.98%. Currently, AbbVie has a market capitalization of $394.19 billion.
San Diego, CA – September 27, 2025 – LENZ Therapeutics (NASDAQ: LENZ) is facing heightened scrutiny this week following a significant insider share sale by a major shareholder, Versant Venture Capital VI, L.P., and its affiliated entities. The coordinated disposition of over 135,000 shares, valued at more than $5.7
Langhorne, PA – September 27, 2025 – Investors in NEXGEL Inc. (NASDAQ: NXGL), a company at the forefront of hydrogel technology, are closely watching the trajectory of its equity warrants (NXGLW). While NEXGEL has demonstrated impressive revenue growth and expanding gross margins, its persistent unprofitability and a recent "going concern" disclosure have
Investors with a lot of money to spend have taken a bearish stance on AbbVie (NYSE: ABBV). And retail traders should know. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
